Abiopharma

🔍 Leheny A. Rachel (Executive)

Company: CalciMedica, Inc. (CALC)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 186,729 shares of Common Stock at $0.8033 per share (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 317,655.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Scheibler-Leheny Family Living Trust | shares_owned_after: 3,500.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 1,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Valence Investments SPV IV, LLC | shares_owned_after: 356,989.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Valence Investments SPV V, LLC | shares_owned_after: 66,228.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Valence Investments SPV VI, LLC | shares_owned_after: 316,109.00 | Footnotes: F2

Footnotes:

• F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
• F2: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.